Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cartesian Therapeutics, Inc. (RNAC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.90, with a market capitalisation of $243.25M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.60 to $11.00. This page covers its latest market performance, valuation, price trends and company information.
$243.25M | |
$8.00 | |
$41.87 | |
$5.60 | |
$8.04 | |
103.97K | |
168.82K | |
-- | |
$11.00 | |
$5.60 | |
-- | |
-- |
Cartesian Therapeutics, Inc. (RNAC) is trading at $8.20 in pre-market trading as of 2026-09-15 23:31:00, up 1.93% ($0.16) from the previous close of $8.04
Pre-market trading shows how investors are pricing RNAC before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Cartesian Therapeutics, Inc. (RNAC) moved from $9.27 to $7.90, representing a decline of 14.77% ($1.37).
The stock traded between $7.67 and $9.31 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 99.84 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 42.6%
RNAC is currently trading at $7.90, placing it 42.6% of the way from its 52-week low of $5.60 to its 52-week high of $11.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cartesian Therapeutics, Inc. (RNAC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.